Pfizer is playing catch-up in the crowded field of obesity medicines, but it hoped to compete with a daily pill alternative to currently available injectable GLP-1 products. Instead, Pfizer is ...

Bayer has filed separate lawsuits against the creators of three COVID-19 vaccines, claiming they violated intellectual ...

Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer recently shed light on. Cramer highlighted some of the stock’s possible catalysts, as he commented: “All right, next up, controversial, it’s ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. The $100 billion obesity market is dominated by injectables, but oral solutions ...

As we previously discussed, beginning in 2022, a series of patent infringement lawsuits were filed against Moderna and collaborators Pfizer+BioNTech seeking damages based on their respective sales of ...

(Bloomberg) -- A judge denied Pfizer Inc.’s request to temporarily block Novo Nordisk A/S’ $10 billion bid to acquire the obesity startup Metsera Inc., saying the US pharmaceutical company’s ...

Pfizer enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution. Click here to read ...